Drugs / LUCORAFUSP ALFA
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05653284 | Feb → Dec 2023 | cancer | Akeso | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06938321 | Apr 2025 → May 2027 expected | biliary tract cancer | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06530251 | Sep 2024 → Jun 2026 overdue | hepatocellular carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07114315 | Sep 2025 → Aug 2027 expected | malignant pancreatic neoplasm | Akeso | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-01-15 | Akeso | 康方PD-1/VEGF双抗依沃西联合卡度尼利/AK130/AK127治疗肝细胞癌Ⅰb/Ⅱ期临床研究获批 akesobio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUCORAFUSP ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068134 ↗ |
| Known as | AK130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07114315 ↗ |
| Modality | Protein / enzyme biologic | “AK130 (TIGIT/TGF-β bifunctional fusion protein)” NCT05653284 ↗ |
| Route | Intravenous | “IV infusion, specified dose on specified days.” NCT05653284 ↗ |